[
    [
        {
            "time": "",
            "original_text": "解禁“魔咒”再现 下周限售股市值大增至1700亿元 解禁",
            "features": {
                "keywords": [
                    "解禁",
                    "限售股",
                    "市值"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "解禁“魔咒”再现 下周限售股市值大增至1700亿元 解禁",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "每日大行评级丨小摩看高耐克至176美元！信义光能遭大和看空 投资评级恶化",
            "features": {
                "keywords": [
                    "耐克",
                    "信义光能",
                    "投资评级",
                    "看空"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费",
                    "能源"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "每日大行评级丨小摩看高耐克至176美元！信义光能遭大和看空 投资评级恶化",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-05-07",
            "original_text": "5月7日晚间重要行业研究汇总(附股)",
            "features": {
                "keywords": [
                    "行业研究",
                    "汇总"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "5月7日晚间重要行业研究汇总(附股)",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【预见】6.34亿股解禁潮来袭！股价已飙涨10倍的药明康德会被砸吗？ 解禁",
            "features": {
                "keywords": [
                    "解禁",
                    "药明康德",
                    "股价",
                    "飙涨"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【预见】6.34亿股解禁潮来袭！股价已飙涨10倍的药明康德会被砸吗？ 解禁",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "药明康德(603259)：CDMO服务增长强劲 全年高增长可期",
            "features": {
                "keywords": [
                    "药明康德",
                    "CDMO",
                    "高增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(603259)：CDMO服务增长强劲 全年高增长可期",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药明康德(603259)：业绩超市场预期 CDMO业务为公司增添业绩弹性",
            "features": {
                "keywords": [
                    "药明康德",
                    "业绩",
                    "CDMO",
                    "弹性"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(603259)：业绩超市场预期 CDMO业务为公司增添业绩弹性",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "中泰国际：上调药明康德(02359)目标价至206.2港元 中国业务持续引领核心盈利快速增长",
            "features": {
                "keywords": [
                    "药明康德",
                    "目标价",
                    "上调",
                    "中国业务",
                    "盈利增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰国际：上调药明康德(02359)目标价至206.2港元 中国业务持续引领核心盈利快速增长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "东吴证券-药明康德2021年一季报点评：业绩高增长，CXO龙头优势显著【公司研究】",
            "features": {
                "keywords": [
                    "药明康德",
                    "业绩",
                    "高增长",
                    "CXO",
                    "龙头"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东吴证券-药明康德2021年一季报点评：业绩高增长，CXO龙头优势显著【公司研究】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]